Daina Graybosch
Stock Analyst at Leerink Partners
(0.09)
# 4,730
Out of 5,051 analysts
501
Total ratings
39.1%
Success rate
-7.8%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Reiterated: Buy | $161 | $145.45 | +10.69% | 79 | Oct 12, 2026 | |
| CRBU Caribou Biosciences | Downgraded: Hold | $1 | $0.4969 | +101.25% | 1 | Oct 7, 2026 | |
| IPHA Innate Pharma | Upgraded: Buy | $2 → $4 | $1.48 | +170.27% | 33 | Aug 11, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $17 | $13.07 | +30.07% | 2 | Aug 3, 2026 | |
| GILD Gilead Sciences | Downgraded: Hold | $129 → $127 | $150.43 | -15.58% | 29 | Jul 20, 2026 | |
| CGEN Compugen | Reiterated: Buy | $13 → $5 | $2.07 | +141.55% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $49 → $47 | $24.34 | +93.10% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $95.84 | +17.90% | 67 | Feb 2, 2026 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $1.44 | +38.89% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Reiterated: Sell | n/a | $17.13 | - | 7 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $1.32 | n/a | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $6 | $4.24 | n/a | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $7 | $2.13 | n/a | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.9818 | n/a | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.08 | n/a | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.74 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.17 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.0003 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $3.79 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $70.78 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $39.84 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.79 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.000001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $4.18 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 35.00 | CHF 3.19 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €84.79 → €89.25 | €138.65 | n/a | 3 | Aug 25, 2020 |
Merck & Co.
Oct 12, 2026
Reiterated: Buy
Price Target: $161
Current: $145.45
Upside: +10.69%
Caribou Biosciences
Oct 7, 2026
Downgraded: Hold
Price Target: $1
Current: $0.4969
Upside: +101.25%
Innate Pharma
Aug 11, 2026
Upgraded: Buy
Price Target: $2 → $4
Current: $1.48
Upside: +170.27%
Replimune Group
Aug 3, 2026
Upgraded: Buy
Price Target: $17
Current: $13.07
Upside: +30.07%
Gilead Sciences
Jul 20, 2026
Downgraded: Hold
Price Target: $129 → $127
Current: $150.43
Upside: -15.58%
Compugen
May 21, 2026
Reiterated: Buy
Price Target: $13 → $5
Current: $2.07
Upside: +141.55%
Arcus Biosciences
Apr 20, 2026
Reiterated: Buy
Price Target: $49 → $47
Current: $24.34
Upside: +93.10%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $95.84
Upside: +17.90%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $1.44
Upside: +38.89%
Summit Therapeutics
Oct 22, 2025
Reiterated: Sell
Price Target: n/a
Current: $17.13
Upside: -
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.32
Upside: n/a
Sep 4, 2025
Reiterated: Hold
Price Target: $20 → $6
Current: $4.24
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $7
Current: $2.13
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.9818
Upside: n/a
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $9.08
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $2.74
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $8
Current: $2.17
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.0003
Upside: n/a
Aug 28, 2024
Reiterated: Hold
Price Target: $6
Current: $3.79
Upside: n/a
Dec 11, 2023
Reiterated: Buy
Price Target: n/a
Current: $70.78
Upside: n/a
Sep 15, 2023
Reiterated: Hold
Price Target: $1.5
Current: $39.84
Upside: n/a
Jun 5, 2023
Reiterated: Buy
Price Target: n/a
Current: $4.79
Upside: n/a
Apr 27, 2022
Reiterated: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $4.18
Upside: n/a
Apr 6, 2021
Reiterated: Buy
Price Target: CHF 35.00
Current: CHF 3.19
Upside: n/a
Aug 25, 2020
Reiterated: Buy
Price Target: €84.79 → €89.25
Current: €138.65
Upside: n/a